Terms: = Breast cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Prognosis
718 results:
1. CircPDE5A-encoded novel regulator of the pi3k/AKT pathway inhibits esophageal squamous cell carcinoma progression by promoting USP14-mediated de-ubiquitination of PIK3IP1.
Lei K; Liang R; Liang J; Lu N; Huang J; Xu K; Tan B; Wang K; Liang Y; Wang W; Lin H; Wang M
J Exp Clin Cancer Res; 2024 Apr; 43(1):124. PubMed ID: 38658954
[TBL] [Abstract] [Full Text] [Related]
2. Elongin B promotes breast cancer progression by ubiquitinating tumor suppressor p14/ARF.
Sui XY; Ma XY; Hou Y; Cao SW; Wang ZQ; Jia LJ; Fan L; Shao ZM; Zhang WJ
Cell Biol Toxicol; 2024 Apr; 40(1):24. PubMed ID: 38653919
[TBL] [Abstract] [Full Text] [Related]
3. The prognosis of patients treated with everolimus for advanced ER-positive, HER2-negative breast cancer is driven by molecular features.
Salaün H; Djerroudi L; Haik L; Schnitzler A; Bataillon G; Deniziaut G; Bièche I; Vincent-Salomon A; Debled M; Cottu P
J Pathol Clin Res; 2024 May; 10(3):e12372. PubMed ID: 38563252
[TBL] [Abstract] [Full Text] [Related]
4. Osteopontin promotes tumor growth and metastasis and GPX4-mediated anti-lipid peroxidation in triple-negative breast cancer by activating the pi3k/Akt/mTOR pathway.
Guo M; Liu M; Li W; Wang C; Zhang L; Zhang H
J Cancer Res Clin Oncol; 2024 Mar; 150(3):155. PubMed ID: 38526702
[TBL] [Abstract] [Full Text] [Related]
5. pik3ca mutation-driven immune signature as a prognostic marker for evaluating the tumor immune microenvironment and therapeutic response in breast cancer.
Ren X; Cui H; Dai L; Chang L; Liu D; Yan W; Zhao X; Kang H; Ma X
J Cancer Res Clin Oncol; 2024 Mar; 150(3):119. PubMed ID: 38466449
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
Lu Q; Wang N; Jiang K; Zhou H; Zhang P; Zhang J; Wang S; Sun P; Xu F
ESMO Open; 2024 Mar; 9(3):102389. PubMed ID: 38460250
[TBL] [Abstract] [Full Text] [Related]
7. SORBS1 inhibits epithelial to mesenchymal transition (EMT) of breast cancer cells by regulating pi3k/AKT signaling and macrophage phenotypic polarization.
Feng K; Di Y; Han M; Yan W; Wang Y
Aging (Albany NY); 2024 Mar; 16(5):4789-4810. PubMed ID: 38451194
[TBL] [Abstract] [Full Text] [Related]
8. Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced breast cancer Receiving Palbociclib: Results From the TREnd Trial.
Migliaccio I; Romagnoli D; Galardi F; De Luca F; Biagioni C; Curigliano G; Criscitiello C; Minisini AM; Moretti E; Risi E; Guarducci C; Nardone A; Biganzoli L; Benelli M; Malorni L
JCO Precis Oncol; 2024 Feb; 8():e2300285. PubMed ID: 38427931
[TBL] [Abstract] [Full Text] [Related]
9. Bioinformatics analysis for the identification of Sprouty-related EVH1 domain-containing protein 3 expression and its clinical significance in thyroid carcinoma.
Zhang X; Meng X; Wang P; Luan C; Wang H
Sci Rep; 2024 Feb; 14(1):4549. PubMed ID: 38402263
[TBL] [Abstract] [Full Text] [Related]
10. The interplay of PTEN and AKT nexus in breast cancer: a molecular perspective.
Kamal A; Awan AR; Rabbani M; Sheikh HR; Tayyab M; Firyal S; Khan IH; Wasim M
Mol Biol Rep; 2024 Feb; 51(1):345. PubMed ID: 38400870
[TBL] [Abstract] [Full Text] [Related]
11. Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort.
Xiong M; Wang X; Liu D; Xiu B; Zhang Q; Chi W; Goh CW; Zhang L; Chen M; Ren H; Shao ZM; Yang B; Wu J
Cancer Med; 2024 Jan; 13(2):e6955. PubMed ID: 38379328
[TBL] [Abstract] [Full Text] [Related]
12. ZNF460-mediated circRPPH1 promotes TNBC progression through ITGA5-induced FAK/pi3k/AKT activation in a ceRNA manner.
Zhang C; Yu Z; Yang S; Liu Y; Song J; Mao J; Li M; Zhao Y
Mol Cancer; 2024 Feb; 23(1):33. PubMed ID: 38355583
[TBL] [Abstract] [Full Text] [Related]
13. GBP2 enhances paclitaxel sensitivity in triple‑negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the pi3k/AKT/mTOR pathway.
Zhang W; Tang X; Peng Y; Xu Y; Liu L; Liu S
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38334171
[TBL] [Abstract] [Full Text] [Related]
14. The emerging role of noncoding RNAs in the pi3k/AKT/mTOR signalling pathway in breast cancer.
Abu-Alghayth MH; Khan FR; Belali TM; Abalkhail A; Alshaghdali K; Nassar SA; Almoammar NE; Almasoudi HH; Hessien KBG; Aldossari MS; Binshaya AS
Pathol Res Pract; 2024 Mar; 255():155180. PubMed ID: 38330621
[TBL] [Abstract] [Full Text] [Related]
15. Bioinformatics analysis identifies coagulation factor II receptor as a potential biomarker in stomach adenocarcinoma.
Wu X; Wang S; Wang C; Wu C; Zhao Z
Sci Rep; 2024 Jan; 14(1):2468. PubMed ID: 38291086
[TBL] [Abstract] [Full Text] [Related]
16. ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis.
Nie J; Dang S; Zhu R; Lu T; Zhang W
Breast Cancer Res; 2024 Jan; 26(1):19. PubMed ID: 38287441
[TBL] [Abstract] [Full Text] [Related]
17. ACEK Biosensor for the Minute-Scale Quantification of breast cancer ctDNA.
Wang K; Lin X; Zhang M; Yang M; Shi X; Xie M; Luo Y
Sensors (Basel); 2024 Jan; 24(2):. PubMed ID: 38257640
[TBL] [Abstract] [Full Text] [Related]
18. The emerging roles of CEACAM6 in human cancer (Review).
Wu G; Wang D; Xiong F; Wang Q; Liu W; Chen J; Chen Y
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38240103
[TBL] [Abstract] [Full Text] [Related]
19. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
Park J; Chang ES; Kim JY; Chelakkot C; Sung M; Song JY; Jung K; Lee JH; Choi JY; Kim NY; Lee H; Kang MR; Kwon MJ; Shin YK; Park YH; Choi YL
Breast Cancer Res; 2024 Jan; 26(1):13. PubMed ID: 38238761
[TBL] [Abstract] [Full Text] [Related]
20. Nanoemulsion potentiates the anti-cancer activity of Myricetin by effective inhibition of pi3k/AKT/mTOR pathway in triple-negative breast cancer cells.
Sharma P; Chaturvedi S; Khan MA; Rai Y; Bhatt AN; Najmi AK; Akhtar M; Mishra AK
Med Oncol; 2024 Jan; 41(2):56. PubMed ID: 38218749
[TBL] [Abstract] [Full Text] [Related]
[Next]
